Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Clinical Trials in Spain / NCT07249294
Active, not recruiting Not applicable

Program to Avoid NSAIDs in Patients With Advanced Chronic Liver Disease

NCT07249294 · tracked via the Priya Life Science Spain tracker
Sponsor
Parc de Salut Mar
Phase
Not applicable
Started
2023-04-01
Last updated
2025-12-03

Condition(s) studied

Advanced Chronic Liver DiseasePortal Hypertension Related to Cirrhosis

Investigational drug(s) / intervention(s)

Multidisciplinary support program

Multidisciplinary support program: The intervention includes guideline updates, automated alerts, and multidisciplinary support program (MSP) with collaboration among Digestive, Anesthesia, Surgery, and Pharmacy services to avoid the use of NSAIDs or metamizole in patients with cirrhosis.

Study summary

This study aims to implement measures to avoid the use of NSAIDs or metamizole in patients with advanced chronic liver disease (ACLD) scheduled for major surgery, which are contraindicated due to increased risk of renal dysfunction such as acute kidney injury (AKI), clinical decompensation such as ascites, and bleeding.

Eligibility

Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria: * Adults (\>18 years) with ACLD scheduled for major surgery * Exclusion Criteria: Absence of ACLD or portal hypertension, lack of informed consent

Primary outcome measure(s)

Trial sites (1)

FacilityCityRegionStatus
Hospital del Mar Barcelona Spain

More Parc de Salut Mar trials in Spain

Intraoperative Radiotherapy in Patients With Brain Metastases Recruiting
Pilot Study of tSCS for Improving Upper Limb Function in People With Multiple Sclerosis Starting soon
Testing Pulse Stimulation to Improve Motor Function in People With ALS: A Pilot Study Recruiting
Use of Intraoperative Radiotherapy in Breast Cancer Enrolling by invitation
Shock Wave Therapy for Lower Limb Lymphedema Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07249294 on ClinicalTrials.gov ↗ ← All trials in Spain